2026 Overall Evaluation Required for CE

Did you attend the conference in person in Chicago? *

Yes

No

Which sessions did you attend in person at the conference in Chicago? *

Beyond the Buzz: the Latest Updates in Gynecologic Oncology - John Moroney, MD

HPV, Dysplasia, ASCCP Guidelines & More - Jennifer Young Pierce, MD, MPH, FACOG

MD/APP Care Model - Nicole Dreibelbis, CRNP, Katherine Mahar, MS, PA

Cardio Oncology - Laraine Chiu, NP

Nurse Navigation - Jackie McGilbra, APRN

Leveraging & Integrating AI - Max Ingersoll, NP

Curative Surgeries in Gyn Onc - Gary Altwerger, MD

Palliative Procedures in Gyn Onc - Yovanni Casablanca, MD

Survivorship & Starting a Survivorship Program at Your Institution - Jessica Walchonski, PA-C

Non-Hormonal Menopause Management - Emily Gehron, DNP, CRNP, AOCNP

Radiologic Interpretation - Carla Harmath, MD

Provider Wellness & Burnout Prevention - Jenna Unke, MMS, PA-C

N/A - purchased on-demand content in lieu of attending live

If you are a pharmacist claiming credit, you must provide your NABP ID and your Date of birth (month and day only) here. *

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Date of birth only requires month and day (not year). Ex: January 25th would be input as 01/25.

Were the 2026 Allied Health Professionals Meeting sessions free of commercial bias? *

Yes

No

Not applicable

The content met the stated learning objectives: *

	Strongly Agree	Agree	Neither Agree or Disagree	Disagree	Strongly Disagree
Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management.	Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management. - Strongly Agree	Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management. - Agree	Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management. - Neither Agree or Disagree	Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management. - Disagree	Demonstrate advanced medical knowledge of current and emerging concepts in gynecologic oncology, including treatment sequencing, molecular profiling, and clinical trial interpretation, to inform evidence-based patient management. - Strongly Disagree
Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making.	Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making. - Strongly Agree	Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making. - Agree	Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making. - Neither Agree or Disagree	Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making. - Disagree	Interpret diagnostic tools and clinical data—including imaging, genetic testing, and circulating tumor DNA (ctDNA)—to better understand accurate diagnosis, prognosis, and therapeutic decision-making. - Strongly Disagree
Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea.	Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea. - Strongly Agree	Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea. - Agree	Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea. - Neither Agree or Disagree	Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea. - Disagree	Apply clinical reasoning and practice-based strategies to recognize, manage, and mitigate treatment-related complications such as neuropathy, ostomy-related challenges, and post-operative nausea. - Strongly Disagree
Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families.	Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families. - Strongly Agree	Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families. - Agree	Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families. - Neither Agree or Disagree	Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families. - Disagree	Utilize effective communication skills to navigate complex discussions, such as medical aid in dying (MAID), survivorship concerns, and caregiver support, within the multidisciplinary care team and with patients and families. - Strongly Disagree

Overall, how would you rate the quality of the content provided at this conference? *

Very Good

Good

Neither Good or Bad

Bad

Very bad

Overall, how would you rate the quality of the speakers at this conference? *

What changes, if any, do you plan to make to your current professional practices and career development plan as a result of completing this activity? *

What aspect of your involvement in a collaborative team changed as a result of this activity? *

What new team strategies will you employ as a result of this activity? *

Overall, how would you rate your course experience? *

Exceeded expectations

Met expectations

Did not meet expectations

Please provide suggestions on how to improve the Allied Health Professionals Meeting. Please be as specific as possible. *

Additional Comments:

You are here

2026 Overall Evaluation Required for CE